Fed. Circ.'s Claim Construction Rule At Stake In Teva Case

Law360, Washington (March 31, 2014, 8:22 PM EDT) -- In taking Teva Pharmaceuticals USA Inc.’s appeal of a ruling invalidating patents covering its multiple sclerosis drug Copaxone, the U.S. Supreme Court could dramatically alter how the Federal Circuit reviews claim construction findings, experts say, with some expecting a decision that will lead to a more deferential standard of review — and fewer Federal Circuit appeals.

The Supreme Court on Monday granted writ of certiorari in Teva v. Sandoz Inc. et al., agreeing to review a July ruling by the Federal Circuit that paved the way...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.